Pancreatic enzyme replacement therapy use in acute pancreatitis – a systematic review of current practice
HPB · 2026
DOI: 10.1016/j.hpb.2026.06.010 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HPB, 2026. Verfasst von Lewis A Hall und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK; Department of HPB and Liver Tran…. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Pancreatitis, Exocrine Pancreatic Insufficiency, Practice Patterns, Physicians'. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Up to two-thirds of inpatients with acute pancreatitis (AP) may develop pancreatic exocrine insufficiency (PEI), persisting long-term in one third. The prevalence, indications, and outcomes of pancreatic enzyme replacement therapy (PERT) following AP remain poorly defined, with limited AP-specific guidance in current international guidelines. This systematic review aimed to determine the prevalence of PERT use after AP and its associated outcomes. METHODS: Medline, via Ovid and Pubmed, and Embase were searched for studies reporting PERT prescription rates, indications, timing, or outcomes during or after AP. Randomised and non-randomised primary studies in adult populations were eligible. Single-proportion random-effects meta-analyses estimated pooled prescribing rates; evidence certainty was assessed using GRADE. RESULTS: Twenty-eight studies (14,874 patients) were included. Pooled PERT prescription rates across non-randomised studies, were 17.8% (95% CI 11.4-26.7%) overall, rising to 28.4% (95% CI 15.5-46.0%) in necrotising AP and 42.7% (95% CI 23.8-64.0%) in severe disease, versus 5.0% (95% CI 0.3-45.5%) in mild disease. Outcomes data were inconsistent across biochemical, symptom, and quality-of-life endpoints; heterogeneity precluded meta-analysis of treatment effect. Overall evidence certainty was low. CONCLUSIONS: PERT is infrequently prescribed after AP, and evidence for its benefit remains inconsistent. Well-designed trials stratified by severity, including patient-reported outcomes, are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK; Department of HPB and Liver Transplantation, Queen Elizabeth Hospital Birmingham, University Hospitals…
- Good Hope Hospital, University Hospitals Birmingham NHS Trust, Birmingham, UK.
- Department of Nutrition and Dietetics, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.
- The Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
- St James' University Hospital, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
- Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, UK; Department of General Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham, UK.
Zitieren
APA
Hall, L. A., Baxter, J. S. S., Powell-Brett, S., Phillips, M. E., Roberts, K. J., Pandanaboyana, S., Smith, A. M., Lee, M., Blencowe, N. S., & Pathak, S. (2026). Pancreatic enzyme replacement therapy use in acute pancreatitis – a systematic review of current practice. HPB. https://doi.org/10.1016/j.hpb.2026.06.010
Vancouver
Hall LA, Baxter JSS, Powell-Brett S, Phillips ME, Roberts KJ, Pandanaboyana S, et al. Pancreatic enzyme replacement therapy use in acute pancreatitis – a systematic review of current practice. HPB. 2026. doi:10.1016/j.hpb.2026.06.010
BibTeX
@article{Hall2026,
author = {Hall, Lewis A and Baxter, Joshua S S and Powell-Brett, Sarah and Phillips, Mary E and Roberts, Keith J and Pandanaboyana, Sanjay and Smith, Andrew M and Lee, Matthew and Blencowe, Natalie S and Pathak, Samir},
title = {Pancreatic enzyme replacement therapy use in acute pancreatitis – a systematic review of current practice},
journal = {HPB},
year = {2026},
doi = {10.1016/j.hpb.2026.06.010}
}
EUVIMED